Ariad Pharmaceuticals - der letzte Thread
Seite 160 von 196 Neuester Beitrag: 25.04.21 00:38 | ||||
Eröffnet am: | 19.09.11 13:39 | von: steven-bln | Anzahl Beiträge: | 5.875 |
Neuester Beitrag: | 25.04.21 00:38 | von: Andreadhata | Leser gesamt: | 541.524 |
Forum: | Hot-Stocks | Leser heute: | 66 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 158 | 159 | | 161 | 162 | ... 196 > |
Die 7$ hat gestern eine starke Unterstützung gezeigt...im Aftermarket bei 7,04$ geschlossen !
Es gibt keinen vernünftigen Grund für Ihre Vermutung.
Ausser das Sie hier versuchen Kurse zu tippen....die ist auch legitim.
Hat aber eher einen Lottospielcharakter
Zeit§ Kurs + Zusatz Umsatz Umsatz kumuliert
10:27:59§ 5,072 80 32.802
Da ist der Hinweis...Back to the Market...doch eher widersprüchlich !
Nochmals, es geht hier nicht um dich, sondern nur um "Ariad"
Ich warte auch schon auf das Schreiben deines Anwalts....der kann ja dann gleich mehrere Dinge in einem Aufwasch abhandeln.....dann wird es für dich günstiger und du musst nicht mehr so viele Klamotten der Enkelkinder bei Ebay verticken um an Kohle zu kommen.
ARIAD Begins Phase 1/2 Trial of Ponatinib in Japan
Trial to evaluate ponatinib in Japanese patients with CML who are resistant or intolerant to prior therapy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 20, 2012-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of ponatinib, the Company’s investigational BCR-ABL inhibitor. The trial is being conducted in Japanese patients with chronic myeloid leukemia (CML) who have failed treatment with dasatinib or nilotinib or with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who have failed prior tyrosine kinase inhibitors. The trial is designed to establish the recommended dose for ponatinib and confirm its anti-leukemic activity in Japanese patients. The Company expects that this trial should provide the incremental clinical data needed for initial regulatory approval of ponatinib in Japan. Japan is the third largest CML market in the world with an annual incidence of 1,300 new patients reported in 2010.
“Many of the world’s foremost thought leaders on CML are in Japan, and we are delighted to be collaborating with many of them to advance the potential uses of ponatinib among Japanese patients with refractory CML,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer of ARIAD. “We are working closely with these CML experts and anticipate that this trial will confirm the results seen with ponatinib in our ongoing Phase 1 and pivotal Phase 2 trials of ponatinib.”
Trial Design
The Phase 1 dose-escalation portion of the trial will have two dose cohorts: 30 mg and 45 mg administered orally once daily. At least six patients will be enrolled in each dose cohort. Once the recommended dose of ponatinib for Japanese patients is determined and safety evaluations have been completed, the Phase 2 portion of the trial will be initiated. The first patient in the trial has been dosed.
The single-arm, open-label Phase 2 component of the trial is expected to begin in the first quarter of 2013 and to enroll an additional 25 adult patients. ARIAD expects to fully enroll the study by mid-year 2013. In the Phase 2 portion of the trial, the primary efficacy endpoint for CML patients in chronic phase will be major cytogenetic response. For CML patients in accelerated phase or blast phase and for Ph+ ALL patients, the primary endpoint will be major hematologic response, defined as complete hematologic response or no evidence of leukemia. The study’s secondary endpoints for all patients will include major molecular response, time to response, duration of response, progression-free survival and overall survival.
For more information about the trial, patients and physicians should visit http://clinicaltrials.gov/ct2/show/...7133?term=ponatinib&rank=1, call the U.S. toll-free number 1-877-621-2302 or the international number 1-617-621-2302, or e-mail inquiries to clinicaltrials@ariad.com.
die belastung durch die atom-ruine wird sichtbar sein/werden.....
Moving AP26113 forward.
ARIAD announced the start of an international Phase 1/2 clinical trial of AP26113 in September 2011. Read the Press Release. The initial Phase 1 dose-escalation portion includes patients with advanced solid tumors, particularly those with NSCLC. Patients enrolled in this multi-center study will be either refractory to available therapies or have no standard treatment available to them. The primary objective of the Phase 1 segment of the Phase 1/2 trial is to determine the initial safety, tolerability, pharmacokinetic profile, recommended dose (anticipated to be once daily) and preliminary anti-tumor activity of AP26113. ARIAD expects to enroll approximately 50 to 60 patients in this portion of the trial.
The trial is currently enrolling patients and ARIAD presented initial proof-of-concept at the ESMO 2012 Meeting. Read the Press Release.
The Phase 2 part of the trial is expected to begin in the second half of 2013 and is currently planned to include five genetically defined patient cohorts, including:
Patients with ALK positive NSCLC who have not previously received an ALK inhibitor
Patients with ALK positive NSCLC who are resistant to at least one ALK inhibitor
Patients with EGFR positive NSCLC who are resistant to at least one prior EGFR inhibitor
Patients with other cancers expressing ALK or other known targets of AP26113
Patients with ALK-positive NSCLC who also have brain metastases
The Phase 2 trial is planned to enroll approximately 80 patients and will provide further data on the preliminary anti-tumor activity of AP26113 in these molecularly defined patient populations.
"
Es läuft nicht richtig rund, gell Kumpel?
Meldung eines Regelverstoßes:
Melder: sleepless13
Zeitpunkt: 26.12.13 21:20
Grund: benutzt mein Avatar"
Es gibt keinen Grund warum das Papier so tief fallen sollte....
Ich sehe eher die 8$ Marke als Ziel an, die es zu reissen gilt.
ARIAD ist zum derzeitigen Zeitpunkt extrem unterbewertet....und das wird der Markt auch noch verstehen..
Bei dem Verlauf der letzten Handelstage....tat sich mir eher der Verdacht auf :
Das der Kursverlauf gezielt beeeinflusst wird...dh. gebremst...es könnte sein , das sich hier große Adressen gezielt positionieren...
Dies bestätigt sich auch dadurch, das nach der Wiederzulassung durch die FDA...die Kursziele im Vergleich zu vor dem STop von Inclusig ,jenseits von gut und böse sind...und jeder Grundlage entbehren.
Noch dazu verfügt ARIAD über 8 Studien in P2 !!!
Davon träumen andere Biotecs.....
Ich denke eher ,der Kurs hat derzeit nichts mit der Bewertung des Unternehmens zu tun.....
Dies wird sich aber zeitnah vermutlich stark ändern